1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for individuals in Culdesac who are battling with opioid abuse and addiction is opioid maintenance therapy. Some facilities and doctors are certified to dispense certain meds to opioid dependent people, many that are opioid-based themselves and are addiction. In low enough doses however, the user does not feel high but also does not experience intense cravings and isn't experiencing opioid withdrawal. Methadone is the first medication tried for this sole purpose, but there are alternative options currently to select from.
Methadone is an opioid and can be taken at an outpatient clinic licensed to dispense the drug, which is taken daily as a pill or liquid. The cost of the med is approximately under $200 per month. Buprenorphine is also an opiate based med, and is a pill often taken one day on, one day off. But different from Methadone which can only be given in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is approximately $300 per month for the generic version of the medication. There is also a type of buprenorphine containing the drug naloxone, that is a med which reverses the effects of opioids. A person consuming this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and costs about $450 monthly. Naltrexone is another medication taken in opioid maintenance therapy, but unlike the other medications aforementioned it's an opiate blocker and isn't an opioid. A person has the choice to take this medication as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 /month.
For All Alcohol and Drug Rehabilitation Centers In Culdesac, Click Here.
